Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Bicara Therapeutics Inc (BCAX)

Bicara Therapeutics Inc (BCAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Jul 2, 7:30AM CDT

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 29.00 (+0.31%)
MarketBeat.com
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer MarketBeat - Fri May 22, 10:09AM CDT

Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the...

BCAX : 29.00 (+0.31%)
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC GlobeNewswire - Thu May 21, 4:00PM CDT

    At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective...

BCAX : 29.00 (+0.31%)
MarketBeat.com
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data MarketBeat - Thu May 14, 4:09PM CDT

Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy...

BCAX : 29.00 (+0.31%)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed May 13, 7:30AM CDT

BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with...

BCAX : 29.00 (+0.31%)
MarketBeat.com
Bicara Therapeutics Q1 Earnings Call Highlights MarketBeat - Mon May 11, 9:07AM CDT

Bicara Therapeutics (NASDAQ:BCAX) said it made progress during the first quarter of 2026 on the development and commercialization strategy for its lead drug candidate, ficerafusp alfa, or FICERA, while...

BCAX : 29.00 (+0.31%)
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire - Mon May 11, 6:30AM CDT

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026 Long-term follow-up...

BCAX : 29.00 (+0.31%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold Barchart - Sun May 10, 4:00PM CDT

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 29.00 (+0.31%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold Barchart - Sat May 9, 4:00PM CDT

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 29.00 (+0.31%)
BCAX's Phase Three Timeline Meets the Market's Patience Threshold Barchart - Fri May 8, 4:02PM CDT

Barchart Research What to Expect from BCAX Earnings BCAX Generated May 8, 2026 Current Price $22.58 EPS Estimate $$-0.64 Consensus Rating Strong Buy Average Move 5.17% BCAX's Phase Three Timeline Meets...

BCAX : 29.00 (+0.31%)

Barchart Exclusives

Cisco Is Up 46% and Oracle Is Down 25% in 2026. The Better Dividend Buy Might Surprise You. Barchart - 1 hour ago
Cisco is up 46% in 2026 while Oracle has slid 25%, and Wall Street sees up to 185% upside for one of them. Here's how the two tech giants compare on value, yield, and dividend growth. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.